These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32886306)

  • 21. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations.
    Tsuda Y; Hirata M; Katayama K; Motoi T; Matsubara D; Oda Y; Fujita M; Kobayashi H; Kawano H; Nishida Y; Sakai T; Okuma T; Goto T; Ogura K; Kawai A; Ae K; Anazawa U; Suehara Y; Iwata S; Miyano S; Imoto S; Shibata T; Nakagawa H; Yamaguchi R; Tanaka S; Matsuda K
    Int J Cancer; 2019 Dec; 145(12):3276-3284. PubMed ID: 31107544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors.
    van IJzendoorn DGP; Matusiak M; Charville GW; Spierenburg G; Varma S; Colburg DRC; van de Sande MAJ; van Langevelde K; Mohler DG; Ganjoo KN; Bui NQ; Avedian RS; Bovée JVMG; Steffner R; West RB; van de Rijn M
    Clin Cancer Res; 2022 Nov; 28(22):4934-4946. PubMed ID: 36007098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-Arrestin2 Inhibits the Apoptosis and Facilitates the Proliferation of Fibroblast-like Synoviocytes in Diffuse-type Tenosynovial Giant Cell Tumor.
    Cao C; Zhang Y; Cheng J; Wu F; Niu X; Hu X; Duan X; Fu X; Zhang J; Zhang X; Ao Y
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):461-470. PubMed ID: 33994368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.
    Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T
    Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
    Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone.
    Ono T; Noguchi R; Yoshimatsu Y; Tsuchiya R; Sin Y; Nakagawa R; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2022 Jan; 35(1):392-399. PubMed ID: 34731453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Sugaya J; Iwata S; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Jul; 33(3):877-885. PubMed ID: 32274656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.
    Al-Ibraheemi A; Ahrens WA; Fritchie K; Dong J; Oliveira AM; Balzer B; Folpe AL
    Mod Pathol; 2019 Feb; 32(2):242-251. PubMed ID: 30206409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors.
    Tang F; Tie Y; Hong WQ; He X; Min L; Zhou Y; Luo Y; Chen SY; Yang JY; Shi HH; Wei XW; Tu CQ
    Ann Surg Oncol; 2021 Oct; 28(11):6453-6463. PubMed ID: 33748895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 36. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1.
    Oyama R; Kito F; Qiao Z; Sakumoto M; Shiozawa K; Toki S; Yoshida A; Kawai A; Kondo T
    In Vitro Cell Dev Biol Anim; 2019 Jan; 55(1):62-73. PubMed ID: 30411273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Nakagawa M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Jul; 33(3):894-903. PubMed ID: 32356243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma.
    Yoshimatsu Y; Noguchi R; Osaki J; Sin Y; Tsuchiya R; Ono T; Akiyama T; Adachi Y; Tanzawa Y; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2024 Jan; 37(1):337-344. PubMed ID: 37907774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.